All items in the Healthy Skepticism Library
All the 20111 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 186 of 202 pages ‹ First < 184 185 186 187 188 > Last ›
HSL4103
Scherr L.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990;113:408
HSL4109
Shepherd R.
Junk mail
Canadian Medical Association Journal 1990;143:14
HSL4110
Shickman MD.
CME’s relationship with industry
Journal of Continuing Education in the Health Professions 1990;10:189-190
HSL4111
Shulkin D.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990;113:407
HSL4113
Solomon SD.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990;322:65
HSL4114
Squires BP.
Editors and advertisers
Canadian Medical Association Journal 1990;143:167
HSL4115
Squires BP.
PAAB: a lesson in self-government
Canadian Medical Association Journal 1990;143:1151
HSL4116
Stein U.
Ginkgo biloba extracts
Lancet 1990;335:475-476
HSL4118
Information or communication? A consumer study of television advertising
Taylor Nelson Research 1990;
HSL4119
Thomas M, Lexchin J.
Responsiveness to physicians' requests for information concerning drug interactions: a comparison of brand and generic companies.
Soc Sci Med 1990;31:(2):153-7
HSL4122
Tilyard MW, Dovey SM.
Placement of advertisements
New Zealand Medical Journal 1990;103:382
HSL4123
Timpany J.
A sample argument
Canadian Medical Association Journal 1990;143:129
HSL4124
Tomson G, Angunawela I.
Patients, doctors and their drugs. A study at four levels of health care in an area of Sri Lanka
European Journal of Clinical Pharmacology 1990;39:463-467
HSL4125
Tomson G, Weerasuriya K.
'Codes' and practice: information in drug advertisements--an example from Sri Lanka.
Soc Sci Med 1990;31:(7):737-41
HSL4126
Van HR, Mazmanian PE, Osborne CE.
Commercial support for CME courses sponsored by medical schools
Journal of Continuing Education in the Health Professions 1990;10:197-210
HSL4127
Venturelli J.
Medical ethics: a dilemma at our doorstep
Annals of the Royal College of Physicians and Surgeons of Canada 1990;23:335
HSL4129
Williams AP, Cockerill R.
Report on the 1989 survey of the prescribing experiences and attitudes toward prescription drugs of Ontario physicians
1990;
HSL4130
Williams EB.
Advertising acyclovir
Lancet 1990;335:288
HSL4131
Zaini J.
Pushing children’s vitamins
HAI News 1990;(51):1-2, 11
HSL4136
Cohen EP.
Are pharmaceutical ads good medicine?
Business and Society Review 1990;73:8-10
HSL4137
Secunda E.
Is TV addicted to drug company PR?
Business and Society Review 1990;73:11-14
HSL4145
Hamer P.
More medication for healthy women!
DES Action Canada Newsletter 1990;(23):1-2
www.web.net/~desact
HSL9482
Halperin JA.
Strategic issues in the Rx-to-OTC switch
Drug Information Journal 1990;24:(1):13-18
HSL9483
Schondelmeyer SW.
Economic aspects of switch
Drug Information Journal 1990;24:(1):57-66
HSL9488
Mela S.
European communities: outstanding white paper proposals for the completion of internal market in the pharmaceutical sector
Drug Information Journal 1990;24:(3):635-638
HSL9490
Monk MR, Smith M.
Product portfolio analysis: SmithKline to SmithKline Beecham
Journal of Pharmaceutical Marketing Management 1990;4:(4):85-96
HSL19871
Morris LA, Banks DB
New Issues in Drug Advertising and Labeling: The Five Advertising End-Runs
Drug Information Journal 1990;24:639-646
http://dij.sagepub.com/content/24/3/639.abstract
HSL9521
Conlan MF.
Drug industry must hold down Medicaid costs or states will
Drug Topics 1989 Dec 11;133:48
HSL19886
Randall H
Drug Promotional Problem Dec 1989
MJA 1989 Dec;151:(532):653
HSL3984
Wade VA, Mansfield PR, McDonald PJ.
Drug companies' evidence to justify advertising.
Lancet 1989 Nov 25;2:(8674):1261-3
HSL15824
Rodwin MA.
Physicians' conflicts of interest. The limitations of disclosure
NEJM 1989 Nov 16;321:(20):1405-1408
http://content.nejm.org/cgi/content/brief/321/20/1405
HSL19911
SKF Withdraws APMA Resignation
Australian Pharmaceutical Manufacturers Association 1989 Nov 10
HSL4021
Wilkes MS, Shuchman M.
Pitching doctors.
N Y Times Mag 1989 Nov 5;88, 90, 126, 128-129
HSL4019
MaLAM letter follow up—Merck Sharp & Dohme. Are MSD’s distributors uncontrollable?
MaLAM Newsletter 1989 Nov;
HSL4020
Re: the promotion of uridine triphosphate
1989 Nov;
HSL9519
Prescription drugs: ready for prime time?
National Association of Retail Druggists Journal 1989 Nov;111:26-27, 29-30
HSL9520
West CM.
Independent retail pharmacy in a free-market economy
National Association of Retail Druggists Journal 1989 Nov;111:54-57
HSL19912
Margo J
APMA withdraws news release
The Sydney Morning Herald 1989 Oct 307
HSL19910
Margo J
Drug Firm Quits After Findings on Complaints
The Sydney Morning Herald 1989 Oct 267
http://newsstore.smh.com.au/apps/viewDocument.ac?page=1&sy=smh&kw=Drug+firm+quits+after+findings+on+complaints&pb=smh&dt=selectRange&dr=entire&so=relevance&sf=text&sf=headline&rc=10&rm=200&sp=nrm&clsPage=1&docID=news891025_0291_2188
HSL4017
Cearnal ME.
Journal advertising works
Medical Marketing & Media 1989 Oct 20;24:(12):4,6-10
HSL4013
Re: the promotion of DPT-P vaccine
1989 Oct;
HSL4014
MaLAM letter follow up—Wellcome: a welcome withdrawal
MaLAM Newsletter 1989 Oct;
HSL4015
Re: the promotion of Franol combination for asthma
1989 Oct;
HSL9516
Gervas JJ.
Analysis of the factors inducing the prescription
Farmacia Clinica 1989 Oct;6:588-590, 592-594
HSL9518
Johnson RC.
Seeking sanity in an insane world
California Pharmacist 1989 Oct;37:24, 26-27
HSL9537
Zellmer WA.
Generic drug products.
Am J Hosp Pharm 1989 Oct;46:(10):2005
HSL16719
Wolfe SM.
The right to know belatedly comes to the health care system.
Internist 1989 Oct;30:(9):12-4
http://www.ncbi.nlm.nih.gov/pubmed/10295873
HSL3962
Lexchin J.
Declaration of vested interest.
Lancet 1989 Sep 30;2:(8666):806
HSL3936
Engler RL.
The arrhythmia consultation program.
N Engl J Med 1989 Sep 28;321:(13):908
HSL3953
Jarman J.
SKF marketing of hepatitis B vaccine.
N Z Med J 1989 Sep 13;102:(875):481
HSL3954
Kawachi I.
Fenoterol.
N Z Med J 1989 Sep 13;102:(875):478
HSL5287
Borgiel AE, Dunn EV, Lamont CT, MacDonald PJ, Evensen MK, Bass MJ, Spasoff RA, Williams JI.
Recruiting family physicians as participants in research.
Fam Pract 1989 Sep 01;6:(3):168-72
HSL9525
Hearing blasts drug manufacturers' emphasis on R&D for me too drugs
American Pharmacy 1989 Sep;29:16
HSL9526
Exposing the inequities: Senate hearing examines prescription drug prices
National Association of Retail Druggists Journal 1989 Sep;111:30-36
HSL9527
Levy RA, Smith DL.
Staying the course: refill reminders can boost sales
Pharmaceutical Executive 1989 Sep;9:74, 76, 78
HSL9528
Koberstein W.
Pitching to new players
Pharmaceutical Executive 1989 Sep;9:12
HSL9529
Schwartz H.
Docs, Danes and dogs: sampler for the industry
Pharmaceutical Executive 1989 Sep;9:18, 20
HSL9530
Bamberger DR.
Industry responds to new law on drug diversion
Pharmaceutical Executive 1989 Sep;9:100, 102, 104, 106
HSL3980
Spiro M.
Genentech, Inc, and symposium sponsorship.
Ann Emerg Med 1989 Aug;18:(8):908-9
HSL4010
Children’s vitamin preparations: kidding the kids and their parents
1989 Aug;4:(8):109-110
HSL4011
Re: the promotion of serrapeptase
1989 Aug;
HSL4012
Greenwood J.
Prescribing and salesmanship
HAI News 1989 Aug;(48):1-2, 11
HSL9509
Marsh P.
Prescribing for medical and other headaches
Eastern Pharmacist 1989 Aug;32:63-65
HSL9517
Gagnon JP.
Defining and marketing value-added pharmacy services in a community pharmacy. Part 1
Pharmacy Times 1989 Aug;55:61-62, 66-67
HSL9539
Nonprescription drug industry urges more prescription-to-nonprescription switches
American Journal of Hospital Pharmacy 1989 Aug;46:1512
HSL13305
Rao AR, Monroe KB.
The Effect of Price, Brand Name, and Store Name on Buyers' Perceptions of Product Quality : An Integrative Review.
Journal of Marketing Research 1989 Aug;26:(3):351-357
http://web.archive.org/web/20080510112957/http://www.marketingpower.com/content17866.php
HSL3955
Kiatboonsri P, Richter J.
Dipyrone trials in Thailand.
Lancet 1989 Jul 8;2:(8654):107
HSL9532
McLeod DC.
Nonprescription drug approval: therapeutic strategy or marketing decision?
DICP 1989 Jul-Aug;23:(7-8):606-9
HSL3979
Solomon SD.
We need ethical guidelines for promotion of prescription drugs to physicians.
N Engl J Med 1989 Jun 22;320:(25):1700
HSL3961
Lexchin J.
Advertising drugs to the public.
Lancet 1989 Jun 17;1:(8651):1392-3
HSL3978
Scott HV, Ketelbey JW.
Lederfen-F GP trial.
N Z Med J 1989 Jun 14;102:(869):299-300
HSL3966
Massam D.
Promotion of medicines.
Lancet 1989 Jun 10;1:(8650):1330
HSL4006
MaLAM letter follow-up—Merck Sharp & Dohme. Denial of responsibility
MaLAM Newsletter 1989 Jun;
HSL4007
Re: the promotion of tetracycline syrups for children
1989 Jun;
HSL4009
Re: the promotion of buflomedil
1989 Jun;
HSL9535
Schwartz H.
Prescriptions for profit: muckraking journalism on the PBS frontline
Pharmaceutical Executive 1989 Jun;9:14, 16, 18
HSL9546
Manasse HR Jr.
Medication use in an imperfect world: drug misadventuring as an issue of public policy, Part 2.
Am J Hosp Pharm 1989 Jun;46:(6):1141-52
HSL857
Mansfield PR.
Drug advertising.
Lancet 1989 May 20;1:(8647):1137-8
HSL3977
Schwartz TB.
Endorsement of "patient promise" program.
N Engl J Med 1989 May 18;320:(20):1354-5
HSL4005
Miller A, Barrett T, Bradburn E.
Pitching to patients
1989 May 8;40-41
HSL4002
IFPMA marketing code in new booklet, available in three languages
Health Horizons 1989 May;
HSL4003
Re: the promotion of nicergoline
1989 May;
HSL4004
Drug utilization bibliography
1989 May;
HSL9523
Schwartz H.
To prescribe or not? Essential and excessive use of pharmaceuticals
Pharmaceutical Executive 1989 May;9:14, 16, 18
HSL9542
McLaughlin SS.
Novel promotional activities, direct-to-consumer advertising subjects of FDA scrutiny
American Journal of Hospital Pharmacy 1989 May;46:870, 875
HSL3951
Holden C.
Research group forswears financial ties to firms whose drugs it tests.
Science 1989 Apr 21;244:(4902):282
HSL19885
Randall H
Drug Promotion Problems
MJA 1989 Apr 17;150:(531):463
HSL4000
Humphrey AR.
Treatment of herpes zoster.
N Z Med J 1989 Apr 12;102:(865):168
HSL3975
Relman AS.
Economic incentives in clinical investigation.
N Engl J Med 1989 Apr 6;320:(14):933-4
HSL3999
Healy B, Campeau L, Gray R, Herd JA, Hoogwerf B, Hunninghake D, Knatterud G, Stewart W, White C.
Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery.
N Engl J Med 1989 Apr 6;320:(14):949-51
HSL3998
Moulds RF, Wing LM.
Drug advertising.
Med J Aust 1989 Apr 3;150:(7):410-1
HSL3995
This month’s MaLAM letter—Glaxo. Multiple claims, little improvement
MaLAM Newsletter 1989 Apr;
HSL3996
Logarta JD.
Generics revisited: an overdose of expectations
Drug Monitor 1989 Apr;4:(4):49-54
HSL3997
Vreeland LN.
The selling of Retin-A
Money 1989 Apr;75-80, 84, 87
HSL9536
Weiner JN.
Direct advertising of prescription drugs to consumers
Pennsylvania Pharmacist 1989 Apr;70:140-141
HSL9538
Cramer PK.
States' substitution laws squeeze industry innovators
Pharmaceutical Executive 1989 Apr;9:74, 76, 78, 80
HSL3994
Prescriptions for profit
1989 Mar 28;
HSL3934
Dixon RE.
Medical advice by celebrities.
N Engl J Med 1989 Mar 16;320:(11):742
HSL3948
Heery PJ.
What influences prescribing--scientific articles or promotional pressure?
Med J Aust 1989 Mar 6;150:(5):282,
HSL9544
Rosendahl I.
Warner-Lambert readies Rx/OTC product launches
Drug Topics 1989 Mar 6;133:75
Page 186 of 202 pages ‹ First < 184 185 186 187 188 > Last ›
